Superworth

Bone Biologics price to book ratio BBLG

Market value divided by the book value of the company's net assets, since 2022.

Today, Nov 2, 2026
0.2×
5-year median
0.5×
Against its 5-year history
0th
percentile: 0 is its lowest day, 100 its highest
5-year range
0.2× to 2.2×
Peer median
0.2×

Bone Biologics' price to book ratio is 0.2× as of Nov 2, 2026.

That is below its 5-year median of 0.5×, lower than on 100% of days in the last 5 years.

Over that time it ranged from 0.2× in Nov 2026 to 2.2× in Apr 2022.

The median for 10 medical instruments and supplies stocks of a similar size is 0.2×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.2×0.2×0.6×
20250.5×0.4×1.1×
20240.6×0.3×1.5×
20230.5×0.3×0.6×
20220.4×0.3×2.2×

Against its peers

Companies in Medical - Instruments & Supplies nearest Bone Biologics' size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Bone Biologics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.